Inclusion Criteria Umbrella Phase 1b & 2:

          -  Histologically or cytologically confirmed locally advanced/metastatic (Stage IIIB-IV)
             NSCLC.

          -  At least one measurable lesion per RECIST v1.1 at Screening.

          -  ECOG Performance Status 0 or 1.

          -  Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

          -  Adequate hepatic, renal, and bone marrow function.

        Additional Inclusion Criteria for Sub-Study A Phase 1b &2:

        -BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or
        NGS assay and documented in a local pathology report.

        Additional Inclusion Criteria for Sub-Study A Phase 1b only:

        -Any line of therapy for locally advanced/metastatic NSCLC.

        Additional Inclusion Criteria for Sub-Study A Phase 2 only:

        -Previously untreated for locally advanced/metastatic NSCLC

        Additional Inclusion Criteria for Sub-Study B Phase 1b only::

        -Any line of therapy for locally advanced/metastatic NSCLC.

        Additional Inclusion Criteria for Sub-Study B Phase 2 only:

          -  Previously untreated for locally advanced/metastatic NSCLC (Arms B1 & B2), or

          -  One or 2 prior lines of therapy for advanced/metastatic NSCLC (Arm B3), including
             immune checkpoint inhibitor treatment + chemotherapy, and have progressed during or
             after that therapy.

          -  PD-L1 TPS ≥1%

        Exclusion Criteria Umbrella Phase 1b &2:

          -  Active or prior autoimmune disease that might deteriorate when receiving an
             immunostimulatory agent.

          -  Active, non-infectious pneumonitis, pulmonary fibrosis, or known history of
             immune-mediated pneumonitis.

          -  Active infection requiring systemic therapy.

          -  Clinically significant cardiovascular disease.

          -  Other malignancy within 2 years of first dose, with exceptions.

          -  Symptomatic brain metastasis, with exceptions.

        Additional Exclusion Criteria for Sub-Study A Phase 1b&2:

          -  EGFR mutation, ALK fusion oncogene, or ROS1 rearrangement.

          -  Prior treatment with any BRAF inhibitor or MEK inhibitor.

        Additional Exclusion Criteria for Sub-Study A Phase 2 only:

        -Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.

        Additional Exclusion Criteria for Sub-Study B Phase 1b&2:

        -Documentation of any tumor-driving molecular alteration (eg, BRAF, EGFR, ALK)

        Additional Exclusion Criteria for Sub-Study B Phase 2 only:

          -  Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.(Arms B1 & B2)

          -  Confirmed progressive disease on 1st or 2nd imaging tumor assessment after initiation
             of therapy for advanced/metastatic NSCLC.